Research programme: complement factor 5a inhibitors - Jerini

Drug Profile

Research programme: complement factor 5a inhibitors - Jerini

Alternative Names: JPE-1375; JSM-1375; JSM-7717

Latest Information Update: 24 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jerini
  • Developer Jerini; Jerini Ophthalmic
  • Class Small molecules
  • Mechanism of Action Complement C5a inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Age-related macular degeneration; Inflammation

Most Recent Events

  • 10 Apr 2008 Jerini Ophthalmic signs an exclusive licensing and development agreement with PR Pharmaceuticals to develop sustained-release formulations for a variety of ophthalmic indications, including JPE 1375 for age-related macular degeneration
  • 09 Nov 2007 JSM 7717 and JPE 1375 are available for partnering for renal therapy (http://www.jerini.com)
  • 09 Nov 2007 JPE 1375 is available for licensing (http://www.jophth.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top